FDA Approves Kyprolis & #174; (Carfilzomib) for Combination Use in the Treatment of Patients with Relapsed Multiple Myeloma

< p > Approval Expands Kyprolis Indication. Patients Treated With Kyprolis in Combination With Standard of Care Lived 50 Percent Longer Without Disease Worsening Compared to Standard of Care Alone in Pivotal Study < /p >

Source: International Myeloma Foundation - July 24, 2015 Category: Hematology Source Type: news